Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

NCT06500819 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Sarcoma
Osteosarcoma

Interventions

DRUG: B7-H3CART Dose (Intravenous)

Sponsor

Stanford University